Cleanser — Comparison & Upgrade Guide

Key Technical Parameters #

Reformulating a cleanser is not the same as launching one. The brief sounds simple — “upgrade our current formula to be more premium” — but what brand partners usually mean is: reduce irritation, improve sensory, or hit a new market claim. Those three objectives pull the formulation in different directions. Where this gets complicated is that most existing cleansers on the market weren’t designed with upgrade pathways in mind. They were designed to a price point. When you come to us with an existing formula, the first thing we do is run it through what we internally call our CX-Baseline audit — a systematic comparison across five functional parameters that tells us exactly where the performance gap sits before we touch a single ingredient.

This guide covers how we evaluate competing cleanser technologies and generation gaps, which parameters actually drive consumer perception versus which ones look good in a spec sheet, and how we frame the upgrade decision with real performance thresholds.

Where Old Formulas Break Down First #

The failure pattern we see most consistently is this: a brand has been running a SLS-based foaming cleanser for three to five years. It performs fine by basic metrics. Then their retail partner flags rising return rates and comment sentiment shifts toward “tight skin,” “dry after washing,” and “doesn’t feel clean anymore” — which is contradictory, but that’s how consumers talk. The brand assumes fragrance or preservative is the culprit. We get the brief.

When we bench the formula, the issue is almost never fragrance. It’s that the base surfactant system — typically sodium lauryl sulfate at 8–12% actives — hasn’t changed, but the water supply, production batch size, and fill temperature tolerance have drifted over manufacturing cycles. SLS is unforgiving to process variation. Above 38°C fill temperature, it can push free-ion activity higher than the formula was designed to handle, which shows up as post-wash TEWL elevation in our in-house skin model testing. We see this in roughly one in three reformulation audits on conventional foaming systems.

There’s a second failure mode that’s less obvious. Brands that launched on amino acid surfactants three to four years ago — back when sodium cocoyl glutamate was the upgrade answer to everything — are now running into a different wall. The mildness story is solid, but the foam volume and rinse clarity they promised retailers have aged poorly against newer glycinate and taurate blends that deliver comparable mildness at lower active loading. Their formula isn’t wrong. It’s just not competitive anymore.

That’s the real meaning of “upgrade” in this category. Sometimes it’s about fixing a defect. But more often, it’s about staying ahead of what the next generation of mild surfactants can do.

The Five Parameters That Actually Predict Performance #

When we run the CX-Baseline audit, we score every formula against five parameters. Not ten, not two. Five. Here’s what they are and why each one matters.

1. Surfactant mildness index (SMI) — target ≤ 1.8 on our internal zein solubilization scale. This correlates reasonably well with clinical TEWL outcomes, though we’re the first to admit the correlation isn’t perfect across every skin type. Formulas built on SLS alone typically score between 3.2 and 4.5. Amino acid blends land between 0.9 and 1.6 depending on co-surfactant choice. Amphoteric-dominant systems using cocamidopropyl betaine as the primary — not the co-surfactant — sit around 1.4 to 2.2. The number that separates “sensitive skin claimable” from “general use” in our filing experience is roughly 1.8.

2. Foam quality index — volume, density, and rinse speed combined. This is one parameter where consumer perception diverges from irritation data. A formula can score excellent on mildness and still get poor reviews because foam collapses too fast or leaves a greasy residue. Taurate-based systems consistently outperform glutamate on foam persistence (typically 20–35% longer foam half-life in our rotational foam test), which matters for rinse-off perception even if the mildness scores are comparable.

3. pH stability under production conditions. Target range for skin-compatible cleansers is 4.5–5.5. The problem is that many co-surfactants and conditioning agents have strong pH-buffering effects that pull formulas outside this range as batch size scales. We’ve seen gel cleansers formulated and approved at pH 5.0 at 5kg lab scale drift to pH 5.8–6.1 consistently at 200kg production scale due to carbomer neutralization variance. That doesn’t sound like much. But above pH 6.0, the preservative efficacy of phenoxyethanol drops measurably, and you’re now also outside the positioning window for microbiome-friendly claims.

4. Active delivery retention after rinsing. This parameter is essentially invisible in most audits because brands assume rinse-off means zero actives remain. That’s not correct for film-forming conditioning agents, certain cationic polymers, and encapsulated ingredients. For brands adding niacinamide, panthenol, or hyaluronic acid to a cleanser, the question isn’t whether the ingredient is present — it’s whether any meaningful amount contacts the skin barrier before rinse-off. In a typical 30-second wash cycle, most water-soluble free actives are gone before rinsing even begins. Encapsulated or polymer-bound actives are a different story, and this is where our encapsulation technology work feeds directly into cleanser upgrade briefs.

5. Fragrance and preservative compatibility under stress. Tested at 40°C/75% RH for 8 weeks. This should be standard but often isn’t in the original development cycle. Fragrance interaction with anionic surfactants — particularly linear alkylbenzene sulfonates — can shift viscosity by ±30% and produce haze in clear gel formats. We flag this at brief intake, not at pilot.

The parameter brands most commonly neglect is number four. They spend the budget on a premium active, put it in the cleanser, and the actives story is essentially fictional from a delivery standpoint. We push back on those briefs every time.

A few things worth noting about this table. The foam half-life numbers for third-gen systems are actually competitive with SLS — something that surprises brand partners who assume mildness comes at a foam cost. It doesn’t, if you formulate with the right co-surfactant ratios. The active retention column is where the generation gap is most stark. And the stability pass rate improvement in third-gen systems reflects better pH buffering and reduced surfactant-fragrance incompatibility, not magic.

Upgrade Decision Framework #

Not every brief needs a full generational upgrade. Here’s how we frame the decision.

If the core consumer complaint is post-wash tightness or dryness: the SMI is almost certainly the issue. Moving from an SLS primary to a 60:40 blend of sodium cocoyl glycinate and cocamidopropyl betaine typically brings SMI from the 3.5–4.5 range into the 1.2–1.6 range without requiring a full formula rebuild. Cost delta at production scale is real — amino acid and taurate surfactants run 3 to 5 times the raw material cost of SLS — but the formula change is contained. Stability requalification takes 8 weeks accelerated plus concurrent 24-month real-time. That’s the minimum, and we don’t negotiate that timeline down.

If the complaint is “doesn’t feel premium” without a specific functional deficit: this is a sensory engineering problem, not an actives problem. Changing surfactant generation won’t fix it. The variables to address are viscosity profile (high-shear versus low-shear feel on skin), rinse-off speed, and post-wash residue. We’d start with a co-surfactant swap and thickener optimization before touching the primary surfactant.

If the brand is launching in the EU or UK and the formula contains cocamide DEA or DMDM hydantoin: the upgrade is not optional. EU Cosmetics Regulation 1223/2009 places cocamide DEA on the restricted list, and formaldehyde-releasing preservatives face mounting SCCS Scientific Opinion review pressure that is likely to result in further restriction in the next two to three years. We build all EU-bound cleansers to avoid this category proactively. Waiting for a regulatory trigger costs more than reformulating ahead of it.

If the brief includes “add actives to the cleanser for a multi-functional claim”: the question we always ask first is what clinical evidence the brand needs to support the claim. A split-face RCT (n=40, 12 weeks) published in 2022 in the Journal of Cosmetic Dermatology demonstrated a 23% reduction in self-reported skin roughness scores in a niacinamide-containing amino acid cleanser versus a matched vehicle control — but the concentration used was 3% niacinamide, and the rinse-off contact time in the study protocol averaged 45 seconds. Most consumers rinse in 15–20 seconds. Whether that efficacy claim survives real-world use conditions is something we’re honestly still not fully settled on. Our current recommendation is to build actives into leave-on steps and use the cleanser claim for barrier compatibility rather than active delivery, unless encapsulation is part of the system. For brands committed to a cleanser-as-treatment positioning, our acid exfoliation technology platform offers better retention data for certain actives than free-form delivery.

On the regulatory side for US brands: FDA Cosmetics Guidelines don’t impose the same restriction structure as the EU, but substantiation expectations for “clinically proven” claims have tightened noticeably since 2022. If the brand plans to use clinical language on pack, we request a pre-claim review before finalizing the formula brief — not after.

One thing we haven’t fully resolved internally is the optimal thickener system for taurate-based cleansers targeting ultra-low viscosity gel formats (below 2,000 cP). Hydroxyethylcellulose gives acceptable clarity but inconsistent shear-thinning profile across temperature cycles. Carbomer gives better control but complicates the mildness story at concentrations above 0.3%. Our current approach is a hybrid at a 1:0.4 ratio, but it’s not elegant and we’re still testing alternatives.

Formulation Notes for Brand Partners #

When you brief us on a cleanser upgrade, the first questions we ask are: What market is this for? What format — gel, cream, oil-to-foam? And what’s the on-pack claim hierarchy you’re building toward?

The reason format matters is that it changes the qualification burden entirely. A gel cleanser reformulation with a surfactant swap involves 8 weeks accelerated stability and a compatibility test across three packaging formats. A cream-to-foam or oil-to-foam conversion is a ground-up development — different emulsification strategy, different preservative screening, different viscosity targets. Treating those as the same scope is the most common brief mistake we see, and it creates misaligned timeline expectations early.

The second thing we flag in every kickoff: brands often brief us on “adding actives” to justify a price increase, when the real driver of perceived premium is sensory. A formula with 3% niacinamide in a SLS base will test worse in blind consumer panels than a well-formulated taurate gel with no actives at all. We redirect the budget to where it actually changes perception.

On timeline: lab samples in 2–3 weeks from locked brief. Accelerated stability runs 4–8 weeks. Twenty-four-month real-time stability is initiated concurrently at the start of accelerated testing, not after it completes.

Frequently Asked Questions #

We want to switch from SLS to something milder — what does that actually cost us per unit?
A: It depends heavily on formula complexity and production volume, but raw material cost for amino acid or taurate primaries runs roughly 3 to 5 times SLS at equivalent actives loading. At a typical production run of 500kg, that cost delta is usually $0.08–$0.18 per unit before formula optimization. Compressing active loading — which is often possible without affecting sensory — reduces the gap.

Does the EU have restrictions on cleanser ingredients we should know about before briefing?
A: Yes, and more are coming. EU Cosmetics Regulation 1223/2009 already restricts cocamide DEA, and the SCCS is actively reviewing several formaldehyde-releasing preservatives still used in some older cleanser formulas. If you’re building for EU distribution, send us the current INCI list before briefing — we’ll flag anything that needs proactive substitution.

What actually goes wrong when you try to add niacinamide or other actives to a rinse-off formula?
A: The most common issue isn’t stability — niacinamide is reasonably stable in most cleanser pH ranges. The issue is that the efficacy story often doesn’t survive real-world rinse time. We’ve run internal contact-time studies where free niacinamide at 3% showed meaningful skin absorption at 45-second contact, but negligible at 15 seconds. Most consumers fall in the 15–25 second range. Unless the active is encapsulated or polymer-bound for extended release, the on-pack claim is hard to substantiate.

What’s the minimum order for a cleanser reformulation project, and how long does sampling take?
A: MOQ for pilot sampling is typically 30kg to generate enough material for stability and consumer testing. Commercial production MOQ runs 200–500kg depending on format and packaging type. Lab samples from a locked brief take 2–3 weeks. If we’re starting from an existing formula audit rather than a blank brief, it’s often faster.

Is it worth adding a “microbiome-friendly” claim to an upgraded cleanser?
A: It depends on what the claim is based on. If it’s purely pH-substantiated — formula pH 4.5–5.5, tested and documented — that’s a defensible, low-cost claim to add. If the brief calls for a probiotic lysate or prebiotic ingredient in a rinse-off format, the efficacy case gets thin fast. Rinse-off contact time doesn’t give prebiotic actives much to work with, and the PCPC Guidelines don’t provide a validated test method for microbiome claims in rinse-off categories. We’re not convinced the clinical evidence for rinse-off prebiotic cleansers is strong enough to justify the cost in most product tiers. For that story to work, it belongs in a leave-on step.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.